Cantor Fitzgerald Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $96

Benzinga Newsdesk www.benzinga.com Positive 76.1%

Neg 0% Neu 0% Pos 76.1%

Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $84 to $96.